z-logo
Premium
Population pharmacokinetics and pharmacodynamics of biapenem in paediatric patients
Author(s) -
Ikawa K.,
Morikawa N.,
Ikeda K.,
Miki M.,
Nishimura S.,
Kobayashi M.
Publication year - 2008
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.2008.00908.x
Subject(s) - pharmacodynamics , pharmacokinetics , medicine , population pharmacokinetics , population , pharmacology , environmental health
Summary Objective:  To develop a population pharmacokinetic model for biapenem in paediatric patients and to use the parameter estimates to assess pharmacodynamic exposure of common bacterial populations. Methods:  Biapenem plasma concentrations ( n  = 125) from 25 paediatric patients were analysed using nonmem . The parameter estimates were used in a Monte Carlo simulation to predict the exposure time during which the drug concentration remains above the minimum inhibitory concentration. Results:  A two‐compartment model fitted the data, and creatinine clearance (CL cr ) and total body weight (TBW) were the most significant covariates. The final model was CL (L/h) = 0·0458 × CL cr , V c (L) = 0·162 × TBW, Q (L/h) = 2·05, V p (L) = 1·73, where CL is the clearance, V c is the volume of distribution of the central compartment, Q is the intercompartmental clearance and V p is the volume of distribution of the peripheral compartment. Biapenem regimens of 5 mg/kg q8h and 10 mg/kg q8h provided sufficient pharmacodynamic exposures to Pseudomonas aeruginosa and Streptococcus pneumoniae in most typical patient populations. Conclusion:  These results better define the pharmacokinetics of biapenem and help in the choice of the appropriate dosage regimens for paediatric.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here